Interim 2025/26 LP.8.1 vaccine effectiveness estimates against COVID-19 from the Canadian Sentinel Practitioner Surveillance Network (SPSN): insights into possible impact of influenza and other respir
2 days ago
- #COVID-19
- #Respiratory Co-infections
- #Vaccine Effectiveness
- Study estimated 2025/26 LP.8.1 vaccine effectiveness (VE) against COVID-19 using data from Canadian Sentinel Practitioner Surveillance Network.
- Overall VE was 48% (95% CI: 21 to 66) at median 9 weeks post-vaccination, with 44% for ages 12-64 and 53% for ages ≥65.
- VE estimates were stable for older adults but varied in younger group when controls included or excluded influenza virus infections.
- Variant-specific VE was 63% against the XFG variant, and lower VE (26%) observed for viruses that failed whole genome sequencing.
- Multiplex testing suggested co-infections, especially with higher non-SARS-CoV-2 viral loads, may influence VE underestimation.